文献速递流行病学与生物统计临床试验与 GCP

暴露前预防用于预防HIV感染:美国预防服务工作组证据报告与系统综述

Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2019-01-01

本系统综述汇总14项随机对照试验(N=18837)、8项观察性研究(N=3884)和7项诊断准确性研究(N=32279),评估口服替诺福韦二吡呋酯/恩曲他滨或替诺福韦二吡呋酯单药暴露前预防(PrEP)的获益与危害。PrEP与安慰剂或不使用PrEP相比降低HIV感染风险(RR 0.46,95%CI 0.33-0.66;I²=67%;绝对风险降低-2.0%,95%CI -2.8%至-1.2%),但依从性欠佳时有效性下降。

要点

  • 口服替诺福韦二吡呋酯/恩曲他滨或单药PrEP与安慰剂或不使用PrEP相比降低HIV感染风险(RR 0.46,95%CI 0.33-0.66)。
  • 依从性≥70%时预防效果更佳(RR 0.27,95%CI 0.19-0.39,I²=0%)。
  • PrEP与肾不良事件(RR 1.43,95%CI 1.18-1.75)和胃肠道不良事件(RR 1.63,95%CI 1.26-2.11)风险增加相关,多数不良事件轻微且可逆。

核心结论

  • 在HIV感染风险增高的成人中,口服替诺福韦二吡呋酯单药或替诺福韦二吡呋酯/恩曲他滨PrEP与安慰剂或不使用PrEP相比降低HIV感染风险,但依从性欠佳时有效性下降。

研究设计与样本

  • 系统综述纳入14项随机对照试验(N=18837)、8项观察性研究(N=3884)和7项诊断准确性研究(N=32279),检索Ovid MEDLINE、Cochrane对照试验中心注册库、Cochrane系统综述数据库和EMBASE至2018年6月,监测至2019年1月。

主要发现

  • PrEP与安慰剂或不使用PrEP相比降低HIV感染风险(11项试验;RR 0.46,95%CI 0.33-0.66;I²=67%;绝对风险降低-2.0%,95%CI -2.8%至-1.2%),随访4个月至4年。
  • 依从性≥70%时预防效果更佳(6项试验;RR 0.27,95%CI 0.19-0.39;I²=0%)。
  • PrEP与肾不良事件风险增加相关(12项试验;RR 1.43,95%CI 1.18-1.75;I²=0%;绝对风险降低0.56%,95%CI 0.09%-1.04%)。
  • PrEP与胃肠道不良事件风险增加相关(12项试验;RR 1.63,95%CI 1.26-2.11;I²=43%;绝对风险降低1.95%,95%CI 0.48%-3.43%)。
  • 预测HIV感染风险的工具有中等区分度(受试者工作特征曲线下面积0.49-0.72),需要进一步验证;美国男男性行为者中PrEP依从性差异大(22%-90%)。

关键数值与推荐

  • PrEP降低HIV感染的相对风险RR 0.46(95%CI 0.33-0.66;I²=67%),绝对风险降低-2.0%(95%CI -2.8%至-1.2%)。
  • 依从性≥70%时RR 0.27(95%CI 0.19-0.39;I²=0%)。
  • 肾不良事件RR 1.43(95%CI 1.18-1.75;I²=0%),绝对风险降低0.56%(95%CI 0.09%-1.04%)。
  • 胃肠道不良事件RR 1.63(95%CI 1.26-2.11;I²=43%),绝对风险降低1.95%(95%CI 0.48%-3.43%)。
  • 预测HIV感染风险的工具受试者工作特征曲线下面积0.49-0.72;美国男男性行为者PrEP依从性22%-90%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 预测HIV感染风险的工具有中等区分度,需要进一步验证。
  • 美国男男性行为者中PrEP依从性差异大(22%-90%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Effective prevention strategies for HIV infection are an important public health priority. Preexposure prophylaxis (PrEP) involves use of antiretroviral therapy (ART) daily or before and after sex to decrease risk of acquiring HIV infection. OBJECTIVE: To synthesize the evidence on the benefits and harms of PrEP, instruments for predicting incident HIV infection, and PrEP adherence to inform the US Preventive Services Task Force. DATA SOURCES: Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and EMBASE through June 2018, with surveillance through January 2019. STUDY SELECTION: English-language placebo-controlled randomized clinical trials of oral PrEP with tenofovir disoproxil fumarate/emtricitabine or tenofovir disoproxil fumarate monotherapy; studies on the diagnostic accuracy of instruments for predicting incident HIV infection; and studies on PrEP adherence. DATA EXTRACTION AND SYNTHESIS: Dual review of titles and abstracts, full-text articles, study quality, and data abstraction. Data were pooled using the Dersimonian and Laird random-effects model for effects of PrEP on HIV infection, mortality, and harms. MAIN OUTCOMES AND MEASURES: HIV acquisition, mortality, and harms; adherence to PrEP; and diagnostic test accuracy and discrimination. RESULTS: Fourteen RCTs (N = 18 837), 8 observational studies (N = 3884), and 7 studies of diagnostic accuracy (N = 32 279) were included. PrEP was associated with decreased risk of HIV infection vs placebo or no PrEP after 4 months to 4 years (11 trials; relative risk [RR], 0.46 [95% CI, 0.33-0.66]; I2 = 67%; absolute risk reduction [ARD], -2.0% [95% CI, -2.8% to -1.2%]). Greater adherence was associated with greater efficacy (RR with adherence ≥70%, 0.27 [95% CI, 0.19-0.39]; I2 = 0%) in 6 trials. PrEP was associated with an increased risk of renal adverse events (12 trials; RR, 1.43 [95% CI, 1.18-1.75]; I2 = 0%; ARD, 0.56% [95% CI, 0.09%-1.04%]) and gastrointestinal adverse events (12 trials; RR, 1.63 [95% CI, 1.26-2.11]; I2 = 43%; ARD, 1.95% [95% CI, 0.48%-3.43%]); most adverse events were mild and reversible. Instruments for predicting incident HIV infection had moderate discrimination (area under the receiver operating characteristic curve, 0.49-0.72) and require further validation. Adherence to PrEP in the United States in men who have sex with men varied widely (22%-90%). CONCLUSIONS AND RELEVANCE: In adults at increased risk of HIV infection, PrEP with oral tenofovir disoproxil fumarate monotherapy or tenofovir disoproxil fumarate/emtricitabine was associated with decreased risk of acquiring HIV infection compared with placebo or no PrEP, although effectiveness decreased with suboptimal adherence.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Chou R, Evans C, Hoverman A, et al. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019. PMID: 31184746. doi:10.1001/jama.2019.2591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。